About
About
About
EVIIVE is a precision oncology company developing blood-based tests that predict how cancer patients will respond to specific immunotherapies before treatment begins.
At EVIIVE, we believe every patient deserves a biomarker that works for them.
More than half of patients treated with approved immunotherapies do not respond, while over 60% of Phase III immuno-oncology trials fail, often due to poor patient stratification. EVIIVE addresses both challenges, helping pharma run more efficient trials and clinicians match patients to the right regimen.
Founded in 2024 as a spin-out from the University of Zurich, EVIIVE is headquartered in Zurich, Switzerland. The melanoma application is licensed from the University of Zurich, while the underlying platform, including the proprietary method and ratiometric approach used for patient stratification, is owned by EVIIVE.
Meet our team
Meet our team
Meet our team
Leadership
Co-Founder & CEO
Molecular immunologist turned entrepreneur with deep EV diagnostics expertise. A former professional mountain biker, he now leads EVIIVE’s vision from bench to market—translating immune insights into investable, clinically meaningful diagnostics.
Co-Founder & CEO
Molecular immunologist turned entrepreneur with deep EV diagnostics expertise. A former professional mountain biker, he now leads EVIIVE’s vision from bench to market—translating immune insights into investable, clinically meaningful diagnostics.
Co-Founder & CEO
Molecular immunologist turned entrepreneur with deep EV diagnostics expertise. A former professional mountain biker, he now leads EVIIVE’s vision from bench to market—translating immune insights into investable, clinically meaningful diagnostics.
Co-Founder & CSO
Innovative molecular & cellular cancer immunologist, recently serving as Prof Dr at the University of Zurich. As scientific architect of EVIIVE’s cutting-edge diagnostic platform, he discovered key biomarkers & translated deep mechanistic insights into novel immuno-oncology diagnostics.
Co-Founder & CSO
Innovative molecular & cellular cancer immunologist, recently serving as Prof Dr at the University of Zurich. As scientific architect of EVIIVE’s cutting-edge diagnostic platform, he discovered key biomarkers & translated deep mechanistic insights into novel immuno-oncology diagnostics.
Co-Founder & CSO
Innovative molecular & cellular cancer immunologist, recently serving as Prof Dr at the University of Zurich. As scientific architect of EVIIVE’s cutting-edge diagnostic platform, he discovered key biomarkers & translated deep mechanistic insights into novel immuno-oncology diagnostics.
Strategic & Commercial Advisor
Life sciences entrepreneur and executive with 20+ years of experience across academia and the biotech industry. Co-founder and former CEO of Proteomedix AG, where he led the development and commercialization of novel prostate cancer diagnostics and the company through its acquisition by Onconetix. He is currently the founding CEO of the Zurich Hub for Drug and Device Development (ZH3D) at the University of Zurich.
Strategic & Commercial Advisor
Life sciences entrepreneur and executive with 20+ years of experience across academia and the biotech industry. Co-founder and former CEO of Proteomedix AG, where he led the development and commercialization of novel prostate cancer diagnostics and the company through its acquisition by Onconetix. He is currently the founding CEO of the Zurich Hub for Drug and Device Development (ZH3D) at the University of Zurich.
Strategic & Commercial Advisor
Life sciences entrepreneur and executive with 20+ years of experience across academia and the biotech industry. Co-founder and former CEO of Proteomedix AG, where he led the development and commercialization of novel prostate cancer diagnostics and the company through its acquisition by Onconetix. He is currently the founding CEO of the Zurich Hub for Drug and Device Development (ZH3D) at the University of Zurich.
Advisors
Clinical Advisor
Global leader in melanoma research and immunotherapy. Vice Chair of Dermatology at University Hospital Zurich, advising on clinical strategy, physician network development, and regulatory planning.
Clinical Advisor
Global leader in melanoma research and immunotherapy. Vice Chair of Dermatology at University Hospital Zurich, advising on clinical strategy, physician network development, and regulatory planning.
Clinical Advisor
Global leader in melanoma research and immunotherapy. Vice Chair of Dermatology at University Hospital Zurich, advising on clinical strategy, physician network development, and regulatory planning.
Commercial Advisor
Former SVP at Roche Diagnostics and General Manager at Abbott. Strategic advisor to ARCHIMED Investment Group. Brings 20+ years of global diagnostics leadership in Go-to-Market, partnerships, and exits.
Commercial Advisor
Former SVP at Roche Diagnostics and General Manager at Abbott. Strategic advisor to ARCHIMED Investment Group. Brings 20+ years of global diagnostics leadership in Go-to-Market, partnerships, and exits.
Commercial Advisor
Former SVP at Roche Diagnostics and General Manager at Abbott. Strategic advisor to ARCHIMED Investment Group. Brings 20+ years of global diagnostics leadership in Go-to-Market, partnerships, and exits.
Strategic & Commercial Advisor
30+ years of full-time Biopharma leadership including P&L responsibility with Pfizer/Wyeth, Novartis/Ciba, Bayer/Schering, MSD. Member of executive leadership teams at national and multi-national level with 11 resp. 54 countries. Worked and lived on Northern and Southern hemisphere as former serial intrapreneur in bringing multiple breakthroughs globally first to market. Business Angel and Board Member with BioValley Basel. Scientific background (BPharm) coupled with multiple executive leadership programs in US, EU, CH, RSA. Tri-lingual.
Strategic & Commercial Advisor
30+ years of full-time Biopharma leadership including P&L responsibility with Pfizer/Wyeth, Novartis/Ciba, Bayer/Schering, MSD. Member of executive leadership teams at national and multi-national level with 11 resp. 54 countries. Worked and lived on Northern and Southern hemisphere as former serial intrapreneur in bringing multiple breakthroughs globally first to market. Business Angel and Board Member with BioValley Basel. Scientific background (BPharm) coupled with multiple executive leadership programs in US, EU, CH, RSA. Tri-lingual.
Strategic & Commercial Advisor
30+ years of full-time Biopharma leadership including P&L responsibility with Pfizer/Wyeth, Novartis/Ciba, Bayer/Schering, MSD. Member of executive leadership teams at national and multi-national level with 11 resp. 54 countries. Worked and lived on Northern and Southern hemisphere as former serial intrapreneur in bringing multiple breakthroughs globally first to market. Business Angel and Board Member with BioValley Basel. Scientific background (BPharm) coupled with multiple executive leadership programs in US, EU, CH, RSA. Tri-lingual.
Strategic & Commercial Advisor
Lars has 20 years of experience in the pharmaceutical and diagnostic industry. He held local and global leadership positions at Roche and AstraZeneca and has extensive experience in the commercialisation of drug-diagnostic combinations in oncology. Lars molecular biologist by training and obtained his PhD from the University of Cambridge.
Strategic & Commercial Advisor
Lars has 20 years of experience in the pharmaceutical and diagnostic industry. He held local and global leadership positions at Roche and AstraZeneca and has extensive experience in the commercialisation of drug-diagnostic combinations in oncology. Lars molecular biologist by training and obtained his PhD from the University of Cambridge.
Strategic & Commercial Advisor
Lars has 20 years of experience in the pharmaceutical and diagnostic industry. He held local and global leadership positions at Roche and AstraZeneca and has extensive experience in the commercialisation of drug-diagnostic combinations in oncology. Lars molecular biologist by training and obtained his PhD from the University of Cambridge.
Awards & Recognition
Awards & Recognition
Awards & Recognition
Venture Kick
All stages
W.A. de Vigier
Top 10
BRIDGE
Proof-of-Concept
Gebert Rüf Stiftung
Innobooster
UZH Entrepreneur
Fellowship
WSS MedTechEntrepreneur
Fellowship
Venture Kick
All stages
W.A. de Vigier
Top 10
BRIDGE
Proof-of-Concept
Gebert Rüf Stiftung
Innobooster
UZH Entrepreneur
Fellowship
WSS MedTech
Entrepreneur Fellowship
